ERCC1、RRM1与BRCA1蛋白联合检测在非小细胞肺癌治疗中的价值分析被引量：1

Value of combined detection of ERCC1, RRM1 and BRCA1 protein in the treatment of non-small cell lung cancer

下载PDF

导出

摘要目的分析ERCC1、RRM1与BRCA1蛋白联合检测在NSCLC治疗中的应用价值。方法观察组患者进行ERCC1、RRM1与BRCA1蛋白联合检测,根据检测结果为患者制定二线化疗方案;对照组患者按照NCCN指南治疗选择任一铂类标准二联一线化疗方案。结果观察组患者的ORR、DCR明显高于对照组,且观察组患者平均PFS、OS均明显长于对照组。结论根据ERCC1、RRM1与BRCA1蛋白联合检测结果为NSCLC患者制定个体化化疗方案有利于控制病情,延长患者生存期,具有推广价值。 Objective:To analyze the value of combined detection of ERCC1,RRM1 and BRCA1 protein in the treatment of NSCLC.Methods:40 patients in each group were tested for ERCC1,RRM1 and BRCA1 protein.According to the test results,the patients in the observation group were given second-line chemotherapy.The patients in the control group were treated with either platinum standard second-line chemotherapy according to NCCN guidelines.Results:The ORR and DCR in the observation group were significantly higher than those in the control group,and the average PFS and OS in the observation group were significantly longer than those in the control group.Conclusion:According to the combined detection results of ERCC1,RRM1 and BRCA1 protein,individualized chemotherapy for NSCLC patients can help to control the disease and prolong the survival time of patients,which is worthy of promotion.

作者秦菁 QIN Jing(Cancer Three Diseases District,Wuhan First Hospital,Wuhan 430022,China)

机构地区武汉市第一医院肿瘤三病区

出处《泰山医学院学报》 CAS 2019年第10期762-763,共2页 Journal of Taishan Medical College

关键词非小细胞肺癌生存期疾病控制率 non-small cell lung cancer survival disease control rate

分类号 R734.2 [医药卫生—肿瘤]

引文网络
相关文献

参考文献5

1尹志永,杨大勇,杨立丰,李华,王铁军,陈丽娜.切除修复交叉互补基因1、核糖核苷酸还原酶M1亚基和3型β微管蛋白分子检测指导晚期非小细胞肺癌个体化治疗的临床效果[J].中国医药导报,2016,13(2):81-84. 被引量：10
2楼燕,武喆,邵吉民,裘云庆.核糖核苷酸还原酶抑制剂的抗病毒作用研究进展[J].中华临床感染病杂志,2016,9(1):83-86. 被引量：2
3王晓艳,赵玉华.切除修复交叉互补酶基因、核糖核苷酸还原酶M1、乳腺癌易感基因1在进展期肺癌组织中的表达及预测意义[J].中国基层医药,2014,21(4):580-582. 被引量：2
4孙江涛,原翔,宋开放,张艳娜.肺癌组织中切除修复交叉互补基因1和核糖核苷酸还原酶亚单位1表达水平与非小细胞肺癌患者的疗效和生存期的关系[J].新乡医学院学报,2017,34(4):270-274. 被引量：9
5陈镜塘.晚期非鳞非小细胞肺癌胸苷酸合成酶和核糖核苷酸还原酶M1的表达及其与化疗疗效的关系[J].广西医学,2016,38(7):945-947. 被引量：4

二级参考文献56

1Martin LP, Hamilton TC, Schilder RJ. Platinum resistance : the role of DNA repair pathways [ J]. Clin Cancer Res,2008,14 ( 5 ) : 1291- 1295.
2Gossage L, Madhusudan S. Current status of excision repair cross complementing-group 1 ( ERCC1 ) in cancer [ J ]. Cancer Treat Rev,2007,33 ( 6 ) : 565-577.
3Ceppi P, Volante M, Novello S,et al. ERCC1 and RRM1 gene ex- pression but not EGFR are predictive of shorter survival in ad- vanced non-small cell lung cancer treated with cisplatin and gem- citabine [ J ]. Ann Onco1,2006,17 (2) : 1818-1825.
4Healy KD, Hodgson L, Kim TY, et al. DLC-1 suppresseslion-small cell lung cancer growth and invasion by RhoGAP-dependent and independent mechanisms [ J ]. Mol Carcinog, 2008,47 ( 5 ) : 326- 337.
5wendum D, Svreek M, Rigau V, et al. COX-2 minflammatory se- creted PLA2, and Cytoplasmic PLA2 protein expression in small bowel adenocarcinoma compared with colorectal edenocarcino-mas [ J ]. Mod Patholm,2003,16 (2) : 130-136.
6Rami Porta R, Crowley JJ, Goldstraw P. The revised TNM staging system for lung cancer[ J]. Ann ThoracCardiovasc Surg,2009,15 (1) :4-9.
7Shao J, Liu X, Zhu L, et al. Targeting ribonucleotide reductase for cancer therapy [ J ]. Expert Opin Ther Targets, 2013, 17 (12) :1423-1437. DOI: 10. 1517/14728222. 2013. 840293.
8Ricardo-Lax I, Ramanan V, Michailidis E, et al. Hepatitis B virus induces RNR-R2 expression via DNA damage response activation[J]. J Hepatol, 2015, 63(4):789-796. DOI: 10. 1016/j. jhep. 2015.05. 017.
9Clouser CL, Chauhan J, Bess MA, et al. Anti-HIV-1 activity of resveratrol derivatives and synergistic inhibition of HIV-1 by the combination of resveratrol and decitabine [ J ]. Bioorg Med Chem Lett, 2012, 22(21 ): 6642-6646. DOI: 10. 1016/j. bmcl. 2012. 08. 108.
10Aye Y, Li M, Long MJ, et al. Ribonucleotide reductase and cancer: biological mechanisms and targeted therapies [ J ]. Oncogene, 2015,34 ( 16 ) :2011-2021. DOI : 10. 1038/onc. 2014. 155.